Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daiichi Sankyo Co., Ltd.
What To Look Out For At ESMO 2024
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention
Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.
Market Access Strategies: Nudging Negotiations Along
Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?
Regeneron’s Linvoseltamab CRL Underlines Risks Of Third-Party Manufacturers
The bispecific antibody is the latest example of a growing number of biologics receiving complete response letters related to third-party manufacturing facilities.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Ambit Biosciences Corporation
- Asubio Pharmaceuticals, Inc.
- Daiichi Sankyo RD Novare Co., Ltd.
- Kitasato Daiichi Sankyo K.K.
- Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
- Plexxikon Inc.
- Ranbaxy Laboratories Ltd.
- Roxro Pharma, Inc.
- Sankyo Pharma
- Suntory Pharmaceutical
- U3 Pharma AG
- Daiichi Sankyo India Pharma Private Limited
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- Zenotech Laboratories Ltd.
- Daiichi Sankyo Vietnam Company Limited.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice